Clinical Trial Update: Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for plasma exchange in severe crescentic IgA nephropathy indicates termination after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Iga Nephropathy
• Rapidly Progressive Glomerulonephritis
• Renal Insufficiency

Snippet

Sponsor: Peking University First Hospital | Conditions: Glomerulonephritis, IGA, Kidney Diseases | Phase 2, Phase 3 | Status: TERMINATED